FDA Broadens Pitolisant Label - Top-Institutions - MDSpire

FDA Broadens Pitolisant Label

The US Food and Drug Administration approves pitolisant (WAKIX) tablets for the treatment of cataplexy in pediatric patients aged 6 years and older with narcolepsy.

  • By

  • Kathryn Wighton

  • February 17, 2026

  • 2 min

Share

Top Institutions in Pediatrics

Brief introduction explaining scope and methodology.

  • #1

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Neurology
    • Sleep Medicine
    • Clinical Research

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Neurology
    • Sleep Medicine
    • Clinical Trials

  • #3

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Neurology
    • Sleep Medicine
    • Translational Research

  • #4

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Neurology
    • Sleep Medicine
    • Neuropharmacology

  • #5

    Harvard Medical School / Massachusetts General Hospital
    Harvard Medical School / Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Neurology
    • Sleep Medicine
    • Clinical Neuroscience

Original Source(s)

FDA Broadens Pitolisant Label

  • by Kathryn Wighton

  • February 17, 2026

Related Content

Perampanel use in pediatric autoimmune encephalitis-related seizures and epilepsy: a retrospective case series

Usefulness of ultrasound in diagnosing constipation in children: a narrative review

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.